TCGA-XF-A9SK-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 15.96583443
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.420
- MYOGENESIS+0.310
- APICAL_SURFACE+0.280
- IL6_JAK_STAT3_SIGNALING+0.230
- APICAL_JUNCTION+0.210
- KRAS_SIGNALING_DN+0.210
- COAGULATION+0.180
- ANGIOGENESIS+0.170
Top 10 suppressed
- E2F_TARGETS-0.670
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V1-0.590
- MYC_TARGETS_V2-0.510
- MITOTIC_SPINDLE-0.470
- MTORC1_SIGNALING-0.340
- PANCREAS_BETA_CELLS-0.300
- ANDROGEN_RESPONSE-0.250
- SPERMATOGENESIS-0.240
- UNFOLDED_PROTEIN_RESPONSE-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0400 | Med | Medulloblastoma | 0.877 |
| 2 | SRR1797234 | — | cohortMD2 | 0.871 |
| 3 | SRR2932812 | — | — | 0.846 |
| 4 | TCGA-UF-A7JJ-01A-11R-A34R-07 | — | — | 0.845 |
| 5 | MDT-AP-1164 | Med | Medulloblastoma | 0.843 |
| 6 | C3L-02560 | — | cohortA1 | 0.842 |
| 7 | MDT-AP-0379 | Med | Medulloblastoma | 0.841 |
| 8 | TCGA-QK-A652-01A-11R-A30B-07 | — | — | 0.833 |
| 9 | TCGA-CV-A45R-01A-11R-A24H-07 | — | — | 0.832 |
| 10 | 20030012.LumA | — | A | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.430 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.280 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.210 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.170 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.060 | Idelalisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.030 | Inavolisib | — uncovered |